Blueprint Medicines Corporation
BPMC
Rank in Stocks
#2351
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Share Price
$129.46
Last synced: 2025-07-18
Market Cap
$8.36B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Blueprint Medicines Corporation (BPMC)
Category
Healthcare
P/E ratio for Blueprint Medicines Corporation (BPMC)
P/E ratio as of October 2026 TTM: -120.99
According to Blueprint Medicines Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -120.99. At the end of 2023 the company had a P/E ratio of -11.02.
P/E ratio history for Blueprint Medicines Corporation from 2013 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -120.99 | 48.06% |
| 2024 | -81.72 | 641.69% |
| 2023 | -11.02 | 135.09% |
| 2022 | -4.69 | -51.84% |
| 2021 | -9.73 | -149.94% |
| 2020 | 19.49 | -267.16% |
| 2019 | -11.66 | 16.64% |
| 2018 | -9.99 | -48.06% |
| 2017 | -19.24 | 80.88% |
| 2016 | -10.64 | 16.86% |
| 2015 | -9.10 | 48.53% |
| 2014 | -6.13 | -48.09% |
| 2013 | -11.81 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -123.79% |
US
|
|
| -28.36 | -76.56% |
US
|
|
| -24.57 | -79.70% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -125.07% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.